# XFOR — X4 Pharmaceuticals Inc · catalysts, narrative & risks

**Deep-research report — K3vl4r**  
**Symbols:** XFOR  
**Sources:** 20  
**Published:** 2026-11-01  
**Canonical:** https://app.k3vl4r.com/research/deep-research-xfor-x4-pharmaceuticals-inc-catalysts-narrative-risks-10531

---

## X4 Pharmaceuticals (Nasdaq: XFOR) — Point-in-Time Research as of 2026-11-01

**Company snapshot.** X4 Pharmaceuticals is a Boston-headquartered clinical-stage biotechnology company centered on the CXCR4 pathway and rare immune/hematologic diseases. Its lead drug, mavorixafor, is marketed in the U.S. and EU as XOLREMDI for WHIM syndrome [[4]](https://www.ad-hoc-news.de/boerse/news/ueberblick/x4-pharmaceuticals-stock-us98423b1052-fda-green-light-for-mavorixafor/69355648)[[20]](https://www.marketbeat.com/stocks/NASDAQ/XFOR/). As of the Oct 30, 2026 close, the stock traded around $3.35 with a market cap of ~$332M, a 52-week range of $2.43–$4.83, and trailing-twelve-month revenue of ~$15.85M against a net loss of ~$90.14M [[16]](https://finance.yahoo.com/quote/XFOR/)[[20]](https://www.marketbeat.com/stocks/NASDAQ/XFOR/).

---

_Preview only. The complete multi-source deep-research report — full thesis, evidence, and citations — is available at https://app.k3vl4r.com/research/deep-research-xfor-x4-pharmaceuticals-inc-catalysts-narrative-risks-10531 (free to sign up)._